Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2020 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies.
Ann Intern Med. 2019 Jan 1;170(1):51-58. doi: 10.7326/M18-1376.
Ann Intern Med. 2019.
PMID: 30596875
Free article.
PROBAST (Prediction model Risk Of Bias ASsessment Tool), a tool for assessing the risk of bias (ROB) and applicability of diagnostic and prognostic prediction model studies, was developed by a steering group that considered existing ROB tools and reporting guideline …
PROBAST (Prediction model Risk Of Bias ASsessment Tool), a tool for assessing the risk of bias (ROB) and applicability of diagnostic …
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV, Petersohn S, Carrera VH, Denniston AK, Chalker A, Raatz H, Armstrong N, Shah D, Witlox W, Worthy G, Noake C, Riemsma R, Kleijnen J, Joore MA.
Pouwels XGLV, et al.
Pharmacoeconomics. 2020 May;38(5):431-441. doi: 10.1007/s40273-019-00851-z.
Pharmacoeconomics. 2020.
PMID: 31701471
Free PMC article.
Review.
The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intravitreal implant (FAc) 0.19 mg (tradename ILUVIEN()), to submit evidence on the clinical and cost-effectiveness of FAc for treating recurren …
The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intr …
Item in Clipboard
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ.
Büyükkaramikli NC, et al.
Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4.
Pharmacoeconomics. 2019.
PMID: 30194622
Free PMC article.
Review.
Patient-level data from the BOLERO-2 trial, evaluating the addition of everolimus to exemestane in the second-line treatment of postmenopausal HR-positive advanced breast cancer, were used to inform the length of progression-free survival during the second line. Costs included in …
Patient-level data from the BOLERO-2 trial, evaluating the addition of everolimus to exemestane in the second-line treatment of postmenopaus …
Item in Clipboard
Digital interventions to moderate alcohol consumption in young people: a Cancer Prevention Europe overview of systematic reviews.
McDermott KT, Noake C, Wolff R, Espina C, Foucaud J, Steindorf K, Schüz J, Thorat MA, Weijenberg M, Bauld L, Kleijnen J.
McDermott KT, et al.
Front Digit Health. 2023 May 23;5:1178407. doi: 10.3389/fdgth.2023.1178407. eCollection 2023.
Front Digit Health. 2023.
PMID: 37288171
Free PMC article.
Review.
Records were independently screened by title and abstract and those that met inclusion criteria were obtained for full text screening by two reviewers. Risk of bias (RoB) was assessed with the ROBIS checklist. We employed a narrative analysis. ...In school-aged children eH …
Records were independently screened by title and abstract and those that met inclusion criteria were obtained for full text screening by two …
Item in Clipboard
Cite
Cite